Neonc Technologies (NASDAQ:NTHI) Given “Sell (E)” Rating at Weiss Ratings

Neonc Technologies (NASDAQ:NTHI)‘s stock had its “sell (e)” rating reiterated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Neonc Technologies Trading Up 6.1%

NASDAQ:NTHI opened at $8.86 on Friday. Neonc Technologies has a one year low of $3.20 and a one year high of $25.00. The firm’s fifty day moving average price is $9.31 and its two-hundred day moving average price is $7.09.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.30) EPS for the quarter.

Hedge Funds Weigh In On Neonc Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. SLT Holdings LLC acquired a new position in shares of Neonc Technologies in the third quarter valued at about $100,000. HCR Wealth Advisors acquired a new position in shares of Neonc Technologies in the second quarter valued at about $54,000. Royal Bank of Canada acquired a new position in shares of Neonc Technologies in the first quarter valued at about $247,000. HighPoint Advisor Group LLC acquired a new position in shares of Neonc Technologies in the first quarter valued at about $290,000. Finally, LVW Advisors LLC bought a new stake in Neonc Technologies during the second quarter worth about $108,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.